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Tamoxifen is an active molecule that is used to treat estrogen-receptor-positive 
breast cancer in both men and women. Estrogen-receptor-positive (ER+) breast 
cancer is where the cancer cells’ growth is promoted by the presence of estrogen. 
Tamoxifen is an antagonist of the estrogen receptors in the breast tissue because it 
blocks the receptors, preventing cancer growth. Three steps were taken to 
synthesize hydrogenated tamoxifen. First, 1-phenyl-1-(p-hydroxyphenyl)-2-
phenylbut-1-ene was synthesized from 4-hydroxybenzophenone and 
propiophenone, using THF as a solvent. Then, the product was amino alkylated to 
synthesize E and Z isomers of tamoxifen, to which it was hydrogenated to produce 
our final product, hydrogenated tamoxifen, or ethanamine. In order to make this 
process more green 2-methyltetrahydrofuran (2-meTHF) was used in place of THF 
wherever possible. 
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• Repeat the alternative step with the Wittig reaction using the solvent that dissolves the 
product. 
• Look for other experimental methods to synthesize 1-phenyl-1-(p-hydroxyphenyl)-2-
phenylbut-1-ene (e.g. Grignard). 
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Tamoxifen is an active ingredient used to treat breast cancer. It is an anti-estrogen 
reagent because it blocks the growth of breast cancer by inhibiting estrogen 
receptors, and is mostly used in the earlier treatment of metastatic breast cancer 
in both men and women. 4-hydroxybenzophenone and propiophenone, using 
titanium chloride as a catalyst, were used as the main reactants for the first step 
of the synthesis of tamoxifen. These reagents were to undergo an Aldol 
condensation reaction to make the desired key intermediate. An Aldol 
condensation reaction requires an enol or an enolate ion to react with a carbonyl 
compound to form a β-hydroxyaldehyde or a β-hydroxyketone. Aldol reactions 
are a good way to form carbon-carbon bonds between two molecules and are 
widely used for pharmaceutical synthesis. Since no product was obtained from 
the Aldol Condensation reaction, a Wittig reaction was carried out using 4-
hydroxybenzophenone, benzyltriphenylphosphonium chlorate, and potassium 
phosphate. A Wittig reaction consists of an aldehyde or a ketone reacted with a 
triphenylphosphonium ylide (called the Wittig reagent) to produce an alkene and 
a triphenylphosphine oxide. This is important in synthesizing organic molecules 
with fixed double bonds. 
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Using the Aldol condensation reaction and later on, the Wittig reaction, the first desired 
intermediate in the synthesis of 1-phenyl-1-(p-hydroxyphenyl)-2-phenylbut-1-ene was 
not obtained. These reactions were characterized by NMR, IR, and TLC and compared 
to literature values. Since no reaction occurred the yields for the individual steps and 
thus the overall yield was unable to be determined. 





Cost $54.60/100mL $85.90/100mL 
Percent yield Not determined Not determined 
E factor Not determined Not determined 
Reaction time, temperature (Step 1) 1 day, 66°C (Step 1) 4 hours, 80°C 
Ease of separation Hard Easy 
Product purity, byproducts Not determined Not determined 
Waste produced Not determined Not determined 
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Green chemistry, which is a method that incorporates less hazardous reagents in 
order to eliminate waste and harm to the environment, was also incorporated into 
this experiment. Had the sought out product been obtained then the three-step 
synthesis would have been repeated using 2-methyltetrahydrofuran (2-meTHF) 
instead of tetrahydrofuran (THF). 2-meTHF reduces the amount of waste 
produced  because of its low miscibility in water and also reduces reaction time 
because of its higher boiling point. During reflux, it also accounts for less solvent 
loss and saves energy during distillation. 
We would like to acknowledge our laboratory instructor Dr. James Wollack and our 
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Figure 1. TLC plate 
developed in 50/50 
toluene/chloroform 
(Aldol). 
Figure 2. TLC plates developed in 1:4 
hexane:ethyl acetate (Wittig). 
Figure 3. TLC plate 
developed in diethyl 
ether (Wittig). 
Figure 4. TLC plate 
developed in ethyl 
acetate (Wittig).  
Spectra 1. 1H-NMR of Aldol reaction with Chloroform-D. Spectra 2. 1H-NMR of Aldol reaction with D2O 
Spectra 3. 1H-NMR of Wittig reaction with Chloroform-D. Spectra 4. Literature 
1H-NMR of 1-phenyl-1-(p-hydroxyphenyl)-2-phenylbut-1-ene 
as referenced by SciFinder. 
The goal was to produce hydrogenated tamoxifen using first an Aldol 
condensation reaction, then an N-alkylation, and lastly an oxidation reaction of an 
alkene group. However, complications arose during the first step when the key 
intermediate was not obtained. This was determined by running NMR (Spectra 1 
and 2) and IR (Spectra 5). NMR and IR did not show peaks expected for the key 
intermediate. TLC (Figure 1) produced an Rf value of 0 which did not match the 
literature Rf  value of 0.35. A Wittig reaction was then used instead of an Aldol to 
produce the key intermediate (see reaction scheme below). The progress of the 
Wittig reaction was monitored by TLC (Figures 2 - 4), but no reaction was 
observed. This signified that the key intermediate was not obtained. After NMR 
spectroscopy, observed peaks (Spectra 3) did not correspond to the literature data 
of the desired product (Spectra 4). Potential sources of error include calculation 
errors in the amount of reagents used. When attempting the Wittig reaction, the 
reaction mixture was refluxed with several different solvents in an attempt to 
identify which one would dissolve it and allow development by TLC. This 
process could have exhausted the product. In the future more precise laboratory 
techniques and equipment can be incorporated to ensure success. 
Spectra 5.  IR of Aldol reaction. 
